Rheumatoid arthritis at a turning point in the era of targeted therapies

The expansion of targeted therapies and the widespread adoption of treat-to-target strategies have substantially improved outcomes for rheumatoid arthritis (RA). However, patient populations remain highly heterogeneous in routine clinical practice. This diversity makes risk-stratified therapeutic selection and shared decision-making essential, particularly when accounting for infection risk, cardiovascular disease, malignancy, thromboembolism, and reproductive considerations. This paper reviews current standard-of-care management and unmet needs while highlighting three priority challenges that may represent future inflection points. First, it proposes a framework for reappraising the pathophysiology of treatment-refractory disease. This model captures the discordance between inflammation and symptoms through persistent inflammatory refractory RA and non-inflammatory refractory RA constructs, while explicitly incorporating reasons for treatment discontinuation. Second, the text addresses the identification of high-risk populations across the continuum from preclinical to early RA and discusses monitoring strategies designed to minimize the risk of overtreatment. Finally, it delineates barriers to implementing precision medicine, including limited access to local biospecimens, challenges in outcome definitions, and complexities in trial design. The paper then outlines a pragmatic, phased roadmap to overcome these hurdles. Translating these concepts into clinical practice would extend and refine conventional treat-to-target paradigms. This approach offers a pathway toward more optimized and individualized therapeutic strategies.